Next Article in Journal
Does Secondary Inflammatory Breast Cancer Represent Post-Surgical Metastatic Disease?
Next Article in Special Issue
Epithelial-Mesenchymal Transition Is a Critical Step in Tumorgenesis of Pancreatic Neuroendocrine Tumors
Previous Article in Journal / Special Issue
Primary Hepatic Gastrinoma Causing Zollinger-Ellison Syndrome: A Rare and Challenging Diagnosis
Article Menu

Export Article

Open AccessArticle
Cancers 2012, 4(1), 141-155; doi:10.3390/cancers4010141

Chromogranin A as Serum Marker for Gastroenteropancreatic Neuroendocrine Tumors: A Single Center Experience and Literature Review

1
Department of Internal Medicine II, Campus Grosshadern, University-Hospital of the Ludwig-Maximilians-University of Munich, Munich 81377, Germany
2
Institute of Medical Informatics, Biometry and Epidemiology, University of Munich, Munich 81377, Germany
3
Department of Clinical Chemistry, Campus Grosshadern, University-Hospital of the Ludwig-Maximilian-University of Munich, Munich 81377, Germany
4
Clinic of Nuclear Medicine, Campus Grosshadern, University-Hospital of the Ludwig Maximilian-University of Munich, Munich 81377, Germany
5
Institute of Radiology, Campus Grosshadern, University-Hospital of the Ludwig Maximilian-University of Munich, Munich 81377, Germany
6
Department of Surgery, Campus Grosshadern, University-Hospital of the Ludwig Maximilians-University of Munich, Munich 81377, Germany
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Received: 30 December 2011 / Revised: 30 January 2012 / Accepted: 10 February 2012 / Published: 15 February 2012
(This article belongs to the Special Issue Neuroendocrine Tumors)
View Full-Text   |   Download PDF [160 KB, uploaded 15 February 2012]   |  

Abstract

The aim of this study was to assess the clinical sensitivities of the tumor markers chromogranin A (CgA), urinary 5-hydroxyindoleacetic acid (5-HIAA) and alkaline phosphatase (AP) in neuroendocrine tumors (NETs) of the GastroEnteroPancreatic-(GEP-) system depending on tumor primary location and metastatic spread. In a retrospective single-center series, sensitivities were evaluated in serum samples from 110 patients with midgut (n = 62) and pancreatic (n = 48) NETs. CgA levels were analyzed by a commercially-available immunoradiometric assay (CIS-bio) during routine follow-up in the years 2000–2009. CgA showed a higher sensitivity for midgut (68%) than pancreatic (54%) NETs. A higher CgA sensitivity and significantly higher median CgA values were found in patients with liver metastases than in those without, and in patients with hepatic and additionally extra-hepatic metastases than in those with hepatic and nodal metastases alone, respectively. We found an overall sensitivity for elevated 5HIAA excretion of 69% for midgut NETs and a significant correlation between median CgA and 5-HIAA values. The sensitivity of AP and the correlations of AP/CgA-data-pairs were low in both midgut and pancreatic NETs, although highest for metastatic pancreatic NETs. The sensitivity of CgA measurement depends on the NET primary location and spread of disease. 5-HIAA and CgA showed comparable sensitivity in midgut NETs, while AP does not seem to be useful as a tumor marker in GEP-NETs. View Full-Text
Keywords: neuroendocrine tumors; gastroenteropancreatic system; sensitivity; chromogranin A; CIS-bio assay; alkaline phosphatase; urinary 5-hydroxyindoleacetic acid; liver metastases neuroendocrine tumors; gastroenteropancreatic system; sensitivity; chromogranin A; CIS-bio assay; alkaline phosphatase; urinary 5-hydroxyindoleacetic acid; liver metastases
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Nölting, S.; Kuttner, A.; Lauseker, M.; Vogeser, M.; Haug, A.; Herrmann, K.A.; Hoffmann, J.N.; Spitzweg, C.; Göke, B.; Auernhammer, C.J. Chromogranin A as Serum Marker for Gastroenteropancreatic Neuroendocrine Tumors: A Single Center Experience and Literature Review. Cancers 2012, 4, 141-155.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top